| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.58B | +33.0% |
| Gross profit | ¥0.24B | — |
| Operating income | ¥0.12B | — |
| Net income | ¥0.10B | +103.1% |
| Gross margin | 42.2% | Net margin 18.0% |
| Revenue Q/Q | +6.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.33B | 57.8% |
| R&D | ¥0.07B | 12.4% |
| SG&A | ¥0.07B | 11.5% |
| Tax & other | ¥0.02B | 2.6% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies